ETON trades 75.5% below Wall Street's consensus target of $57.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ETON achieves its forward estimates and maintains a stable P/E multiple of 40.5x. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 23, 2026, Eton Pharmaceuticals, Inc. (ETON) has a Wall Street consensus price target of $57.00, based on estimates from 6 covering analysts. With the stock currently trading at $32.72, this represents a potential upside of +75.5%. The company has a market capitalization of $896M.
Analyst price targets range from a low of $57.00 to a high of $57.00, representing a 0% spread in expectations. The median target of $57.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ETON trades at a trailing P/E of -192.5x and forward P/E of 40.5x. Analysts expect EPS to grow +1815.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
PRAXPraxis Precision Medicines, Inc. | $8.8B | $303.00 | $584.00 | +106.9% | Buy | — | 16 |
AVDLAvadel Pharmaceuticals plc | $2.1B | $21.64 | $21.43 | -1.0% | Buy | 28.3x | 14 |
TLRYTilray Brands, Inc. | $535M | $4.59 | $10.00 | +111.4% | Hold | — | 20 |
MNPRMonopar Therapeutics Inc. | $460M | $68.66 | $110.00 | +63.0% | Buy | — | 13 |
KALAKALA BIO, Inc. | $78M | $3.54 | $18.25 | +405.5% | Buy | — | 9 |
SLRXSalarius Pharmaceuticals, Inc. | $697790 | $0.74 | — | — | — | — | — |
LNTHLantheus Holdings, Inc. | $6.9B | $106.13 | $108.50 | +4.5% | Buy | 19.4x | 17 |
SUPNSupernus Pharmaceuticals, Inc. | $2.6B | $44.48 | $60.00 | +35.2% | Buy | 17.8x | 14 |
CORTCorcept Therapeutics Incorporated | $8.6B | $79.71 | $83.00 | +3.9% | Buy | 136.5x | 26 |
PAHCPhibro Animal Health Corporation | $1.3B | $31.07 | $49.00 | +53.8% | Buy | 10.4x | 14 |
Quick answers to the most common questions about buying ETON stock.
The consensus Wall Street price target for ETON is $57, representing 75.5% upside from the current price of $32.72. With 6 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ETON has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $57 implies 75.5% upside from current levels.
At a forward P/E of 40.4634x, ETON trades at a premium valuation. The consensus price target of $57 (75.5% upside) suggests analysts still see growth justifying the multiple.
The most bullish Wall Street analyst has a price target of $57 for ETON, while the most conservative target is $57. The consensus of $57 represents the median expectation. These targets typically reflect 12-month expectations.
ETON is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ETON stock forecast based on 6 Wall Street analysts shows a consensus price target of $57, with estimates ranging from $57 (bear case) to $57 (bull case). The median consensus rating is "Buy".
ETON trades at a forward P/E ratio of 40.5x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on ETON, with a "Buy" consensus rating and $57 price target (75.5% upside). 6 of 6 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ETON analyst price targets range from $57 to $57, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $57 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.